Identification and analysis of the risk of liver-related adverse drug reaction in pregnant women

Guangdi MU; Jiayi LI; Yunjuan GAO; Xu ZHAO; Jiabo WANG; Zhaofang BAI; Xiaohe XIAO; Yuming GUO

doi:10.3969/j.issn.1001-5256.2022.08.021

Volume 38 Issue 8

Aug. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(8): 1834-1838

PDF( 2634 KB)

Identification and analysis of the risk of liver-related adverse drug reaction in pregnant women

DOI: 10.3969/j.issn.1001-5256.2022.08.021

Guangdi MU^{1, 2},
Jiayi LI^{2, 3},
Yunjuan GAO²,
Xu ZHAO²,
Jiabo WANG²,
Zhaofang BAI²,
Xiaohe XIAO^{2
,
,
,},
Yuming GUO^{2
,
,
,}

1.
Graduate School, Guizhou University of Traditional Chinese Medicine, Guizhou 550025, China
2.
Department of Liver Disease, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
3.
College of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, China

Research funding:

Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (ZYYCXTD-C-202005);

the National Natural Science Foundation of China (81721002);

Project of China PLA General Hospital (2019MBD-023)

More Information

Corresponding author: XIAO Xiaohe, pharmacy302xxh@126.com(ORCID: 0000-0002-3719-6575); GUO Yuming, guoyuming_0520@126.com (ORCID: 0000-0003-3149-8422)
Received Date: 2021-12-14
Accepted Date: 2022-03-01
Published Date: 2022-08-20

Abstract

Abstract

Objective To investigate the potential medication risk by identifying and analyzing the features of liver-related adverse drug reaction (ADR) in pregnant women. Methods A retrospective study was performed for the reports on liver-related ADR in pregnant women from January 1, 2012 to December 31, 2016 in HILI Cloud (hilicloud.net). Main clinical features and medication rules were analyzed, and reporting odds ratio (ROR) was used to analyze the relative risk of related drugs. Results Methotrexate, mifepristone, and ritodrine were the high-frequency drugs reported for liver-related ADR in pregnant women and were mainly used for termination of ectopic pregnancy and treatment of hydatidiform mole. The relative risk analysis of liver-related ADR showed that in pregnant women, the use of methotrexate (ROR=37.52, 95% confidence interval [CI]=31.35-44.89), progesterone (ROR=7.33, 95%CI: 2.75-19.59), and dydrogesterone (ROR=6.58, 95%CI: 2.20-19.69) was strongly associated with the risk of liver injury, and the association of methotrexate with the risk of liver injury in pregnant women was significantly stronger than that in non-pregnant women (ROR=1.71, 95%CI: 1.47-4.36). Conclusion The potential risk of liver injury should be taken seriously in pregnant women using the drugs such as methotrexate and progesterone, so as to avoid serious adverse reactions.
- Pregnancy,
- Chemical and Drug Induced Liver Injury,
- Drug-Related Side Effects and Adverse Reactions

FullText(HTML)

References(28)

References

[1]	World Health Organization. World patient safety day 2021[EB/OL]. https://www.who.int/newsroom/events/detail/2021/09/17/defaultcalendar/world patient safety day 2021.
[2]	ITO S. Mother and child: medication use in pregnancy and lactation[J]. Clin Pharmacol Ther, 2016, 100(1): 8-11. DOI: 10.1002/cpt.383.
[3]	LI L. Effects of puerarin with insulin aspart on biochemical indexes and artery blood flow parameters related to the fetus of pregnant women with Gestational diabetes[J]. World Chi Med, 2018, 13(5): 1134-1138. DOI: 10.3969/j.issn.1673-7202.2018.05.021. 李玲. 葛根素联合门冬胰岛素对妊娠期糖尿病孕妇生化指标及胎儿相关动脉血流参数的影响[J]. 世界中医药, 2018, 13(5): 1134-1138. DOI: 10.3969/j.issn.1673-7202.2018.05.021.
[4]	World Health Organization, U. M. C. The use of the WHO-UMC system for standardised case causality assessment[EB/OL]. https://www.who-umc.org/media/164200/who-umc-causality-assessment_new-logo.pdf.
[5]	XIAO XH, TANG JM, MAO YM, et al. Guiding principles of clinical evaluation technology of traditional Chinese medicine induced liver injury[J]. Acta Pharm Sin, 2018, 53(11): 1931-1942. https://www.cnki.com.cn/Article/CJFDTOTAL-YXXB201811021.htm 肖小河, 唐健元, 茅益民, 等. 中药药源性肝损伤临床评价技术指导原则[J]. 药学学报, 2018, 53(11): 1931-1942. https://www.cnki.com.cn/Article/CJFDTOTAL-YXXB201811021.htm
[6]	HOU Y, YE X, WU G, et al. A comparison of disproportionality analysis methods in national adverse drug reaction databases of China[J]. Expert Opin Drug Saf, 2014, 13(7): 853-857. DOI: 10.1517/14740338.2014.915938.
[7]	van PUIJENBROEK EP, BATE A, LEUFKENS HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions[J]. Pharmacoepidemiol Drug Saf, 2002, 11(1): 3-10. DOI: 10.1002/pds.668.
[8]	MENG L, TANG XW, JI HH, et al. Mining and evaluation of statin-associated adverse events signals: data mining of the public version of the OpenFDA adverse event reporting system[J]. Chin J New Drugs, 2019, 28(2): 244-248. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYZ201902019.htm 蒙龙, 唐学文, 季欢欢, 等. 他汀类药物相关不良反应的信号挖掘与评价——基于美国OpenFDA公共数据开放项目的数据挖掘研究[J]. 中国新药杂志, 2019, 28(2): 244-248. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYZ201902019.htm
[9]	REN JT, WANG SF, HOU YF, et al. Common signal detection methods of adverse drug reaction[J]. J Pharm, 2011, 8(5): 294-298. DOI: 10.3969/j.issn.1672-8629.2011.05.013. 任经天, 王胜锋, 侯永芳, 等. 常用药品不良反应信号检测方法介绍[J]. 中国药物警戒, 2011, 8(5): 294-298. DOI: 10.3969/j.issn.1672-8629.2011.05.013.
[10]	ZHANG JY, BAI YX, HAN S, et al. Application of data mining algorithm to detect adverse drug reaction signal[J]. ADRJ, 2016, 18(6): 412-416. DOI: 10.3760/cma.j.issn.1008-5734.2016.06.003. 张婧媛, 白羽霞, 韩晟, 等. 数据挖掘方法检测药品不良反应信号的应用研究[J]. 药物不良反应杂志, 2016, 18(6): 412-416. DOI: 10.3760/cma.j.issn.1008-5734.2016.06.003.
[11]	LI SJ, CHEN L, WU S, et al. Analysis and application of measures of dis-proportionality in methotrexate adverse reaction signal mining[J]. Anti-tumor Pharm, 2018, 8(2): 274-278, 287. DOI: 10.3969/j.issn.2095-1264.2018.02.34. 李双娇, 陈力, 吴珊, 等. 比值失衡测量法在甲氨蝶呤不良反应信号挖掘中的应用与分析[J]. 肿瘤药学, 2018, 8(2): 274-278, 287. DOI: 10.3969/j.issn.2095-1264.2018.02.34.
[12]	Ministry of Health, The People's Republic of China. Measures for the administration of adverse drug reaction reporting and monitoring (Order No. 81)[EB/OL]. http://www.gov.cn/zhengce/2011-05/24/content_2603398.htm. 中华人民共和国卫生部. 《药品不良反应报告和监测管理办法》(第81号令)[EB/OL]. http://www.gov.cn/zhengce/2011-05/24/content_2603398.htm.
[13]	SONG SQ, ZHANG GN. Combination chemotherapy of blemycin etoposide cisplatin or carboplatin for the treatment of malignant gestational trophoblastic tumor[J]. Chin J Clin Obstet Gynecol, 2006, (4): 248-250. DOI: 10.3969/j.issn.1672-1861.2006.04.003. 宋水勤, 张国楠. BEP方案治疗恶性滋养细胞肿瘤38例临床分析[J]. 中国妇产科临床杂志, 2006, (4): 248-250. DOI: 10.3969/j.issn.1672-1861.2006.04.003.
[14]	YUAN SW, CEN Y. Diagnosis, treatment and research progress of gestational trophoblastic tumor[J/CD]. J World Latest Med Inf, 2019, 19(48): 324-325. DOI: 10.19613/j.cnki.1671-3141.2019.48.223. 贠舒雯, 岑尧. 妊娠滋养细胞肿瘤的诊治及研究进展[J/CD]. 世界最新医学信息文摘, 2019, 19(48): 324-325. DOI: 10.19613/j.cnki.1671-3141.2019.48.223.
[15]	Gynecological oncology Committee of China Anti Cancer Association. Guidelines for the diagnosis and treatment of gestational trophoblastic diseases (2021 Edition)[J]. China Oncol, 2021, 31(6): 520-532. DOI: 10.19401/j.cnki.1007-3639.2021.06.10. 中国抗癌协会妇科肿瘤专业委员会. 妊娠滋养细胞疾病诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6): 520-532. DOI: 10.19401/j.cnki.1007-3639.2021.06.10.
[16]	WANG LJ, LIN HX, LIN ZQ. Interpretation of 2021 NCCN clinical practice guide for gestational trophoblastic tumor (2nd Edition)[J]. Chin J Pract Gynecol Obstetr, 2021, 37(5): 564-569. DOI: 10.19538/j.fk2021050115. 王丽娟, 林海雪, 林仲秋. 《2021 NCCN妊娠滋养细胞肿瘤临床实践指南(第2版)》解读[J]. 中国实用妇科与产科杂志, 2021, 37(5): 564-569. DOI: 10.19538/j.fk2021050115.
[17]	LIANG Y, MENG Z, CANG HQ, et al. Acute drug-induced liver injury caused by vancomycin hydrochloride for injection: one case report[J]. J Pharm, 2021, 18(8): 789-792. DOI: 10.19803/j.1672-8629.2021.08.20. 梁瑜, 孟真, 仓怀芹, 等. 注射用盐酸万古霉素致急性药物性肝损伤1例分析[J]. 中国药物警戒, 2021, 18(8): 789-792. DOI: 10.19803/j.1672-8629.2021.08.20.
[18]	WANG XQ, HE YB, QIAN ZY, et al. Molecular mechanism of Nifedipine inducing liver injury in children[J]. J Appl Clin Pediatr, 2018, 33(6): 465-469. DOI: 10.3760/cma.j.issn.2095-428X.2018.06.017. 王新启, 贺轶博, 钱致远, 等. 硝苯地平诱发儿童肝损伤的分子机制[J]. 中华实用儿科临床杂志, 2018, 33(6): 465-469. DOI: 10.3760/cma.j.issn.2095-428X.2018.06.017.
[19]	ZHANG YF, YE XJ, CHEN M, et al. A case of acute liver injury caused by ceftriaxone/tazobactam[J]. Chin J Pharmacoepidemiol, 2021, 30(6): 421-422. https://www.cnki.com.cn/Article/CJFDTOTAL-YWLX202106013.htm 张艳芳, 叶旭军, 陈敏, 等. 头孢曲松/他唑巴坦致急性肝损伤1例[J]. 药物流行病学杂志, 2021, 30(6): 421-422. https://www.cnki.com.cn/Article/CJFDTOTAL-YWLX202106013.htm
[20]	HUANG DL, DAI W. A case of acute drug-induced liver injury caused by norethindrone[J]. J Clin Hepatol, 2018, 34(6): 1294-1295. DOI: 10.3969/j.issn.1001-5256.2018.06.033. 黄德良, 戴炜. 炔诺酮致急性药物性肝损伤1例报告[J]. 临床肝胆病杂志, 2018, 34(6): 1294-1295. DOI: 10.3969/j.issn.1001-5256.2018.06.033.
[21]	WANG Y, YE ZK, CUI XL, et al. Pharmaceutical care of a patient with liver injury induced by omeprazole or octreotide[J]. Chin J Clin Pharmacol, 2017, 33(19): 1959-1960. DOI: 10.13699/j.cnki.1001-6821.2017.19.031. 王颖, 叶志康, 崔向丽, 等. 奥美拉唑或奥曲肽致肝损伤1例患者的药学监护[J]. 中国临床药理学杂志, 2017, 33(19): 1959-1960. DOI: 10.13699/j.cnki.1001-6821.2017.19.031.
[22]	KATSUHISA I, HIROAKI Y. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy[J]. Drug Metab Pharmacokinet, 2014, 29(1): 12-19. DOI: 10.2133/dmpk.dmpk-13-rv-119.
[23]	WANG W, ZHOU H, LIU L. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review[J]. Eur J Med Chem, 2018, 158: 502-516. DOI: 10.1016/j.ejmech.2018.09.027.
[24]	BAI ZF, GAO Y, ZUO XB, et al. Progress in research on the pathogenesis of immune regulation and idiosyncratic drug-induced liver injury[J]. Acta Pharm Sin, 2017, 52(7): 1019-1026. DOI: 10.16438/j.0513-4870.2017-0315. 柏兆方, 高源, 左晓彬, 等. 免疫调控与特异质型药物性肝损伤发生机制研究进展[J]. 药学学报, 2017, 52(7): 1019-1026. DOI: 10.16438/j.0513-4870.2017-0315.
[25]	GUO YM, TU C, HE Q, et al. Safety administration strategy for heshouwu (polygoni multiflori radix) based on properties and actions of Chinese medicine[J]. J Tradit Chin Med, 2018, 59(9): 721-724. DOI: 10.13288/j.11-2166/r.2018.09.001. 郭玉明, 涂灿, 何琴, 等. 基于药性功能认知的何首乌安全用药对策研究[J]. 中医杂志, 2018, 59(9): 721-724. DOI: 10.13288/j.11-2166/r.2018.09.001.
[26]	TSAKIRIDIS I, GIOULEKA S, MAMOPOULOS A, et al. Diagnosis and management of ectopic pregnancy: a comparative review of major national guidelines[J]. Obstet Gynecol Surv, 2020, 75(10): 611-623. DOI: 10.1097/OGX.0000000000000832.
[27]	PO L, THOMAS J, MILLS K, et al. Guideline No. 414: management of pregnancy of unknown location and tubal and nontubal ectopic pregnancies[J]. J Obstet Gynaecol Can, 2021, 43(5): 614-630. e1. DOI: 10.1016/j.jogc.2021.01.002.
[28]	HU TX, LYU XQ, LI L, et al. Analysis of 4217 cases of adverse drug reactions induced by progesterone oral agents[J]. J Pharm, 2018, 15(12): 728-732. DOI: 10.3969/j.issn.1672-8629.2018.12.005. 胡婷霞, 吕小琴, 李岚, 等. 4217例黄体酮口服制剂不良反应报告分析[J]. 中国药物警戒, 2018, 15(12): 728-732. DOI: 10.3969/j.issn.1672-8629.2018.12.005.

Relative Articles

[1]	Yu WANG, Qiong LUO, Shu LI, Xiaoping SHEN, Shuang LI, Yanyan TAO, Chenghai LIU. A preliminary study on the peripheral seroimmunological characteristics of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2022, 38(5): 1097-1100. doi: 10.3969/j.issn.1001-5256.2022.05.023
[2]	Wei YAN, Huifang HUANG. Effect of glucocorticoid in the treatment of severe drug-induced liver injury[J]. Journal of Clinical Hepatology, 2022, 38(10): 2302-2307. doi: 10.3969/j.issn.1001-5256.2022.10.019
[3]	Haonan LIU, Yuqin WANG, Meng WU, Tong LU, Yang ZHAO, Zhengxiang HAN. Effectiveness and safety of programmed cell death-1 inhibitor in the treatment of advanced non-HBV non-HCV-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(12): 2761-2766. doi: 10.3969/j.issn.1001-5256.2022.12.015
[4]	Hanping WANG. Adverse reactions associated with immune checkpoint inhibitor in treatment of liver cancer and related treatment measures[J]. Journal of Clinical Hepatology, 2022, 38(5): 985-991. doi: 10.3969/j.issn.1001-5256.2022.05.003
[5]	Feilin GE, Yuming GUO, Ming NIU, Xu ZHAO, Zhaofang BAI, Jiabo WANG, Xiaohe XIAO. Intelligent identification of the big data of liver injury-related adverse drug reactions based on text database[J]. Journal of Clinical Hepatology, 2022, 38(2): 387-391. doi: 10.3969/j.issn.1001-5256.2022.02.024
[6]	Jing JING, Tingting HE, Zhaofang BAI, Jiabo WANG, Ruilin WANG, Xiaohe XIAO. An excerpt from AASLD Practice Guidance on drug, herbal and dietary supplement-induced liver injury[J]. Journal of Clinical Hepatology, 2022, 38(10): 2219-2223. doi: 10.3969/j.issn.1001-5256.2022.10.005
[7]	Yu WANG, Lixia QIU, Zuopeng FAN, Jingjing SONG, Jing ZHANG, Yutao ZHAN. Clinical features of patients with different types of acute drug-induced liver injury: A comparative analysis[J]. Journal of Clinical Hepatology, 2021, 37(3): 632-635. doi: 10.3969/j.issn.1001-5256.2021.03.025
[8]	Yongfeng YANG. Pathological features and pathological diagnosis of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2021, 37(11): 2530-2533. doi: 10.3969/j.issn.1001-5256.2021.11.005
[9]	Xiaoyun LI, Jieting TANG. Epidemiology of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2021, 37(11): 2510-2514. doi: 10.3969/j.issn.1001-5256.2021.11.002
[10]	Yuecheng YU, Chengwei CHEN. Pathogenesis of drug-induced liver injury: Current understanding and future needs[J]. Journal of Clinical Hepatology, 2021, 37(11): 2515-2524. doi: 10.3969/j.issn.1001-5256.2021.11.003
[11]	Wanna YANG, Wen XIE. Clinical manifestations and typing of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2021, 37(11): 2525-2529. doi: 10.3969/j.issn.1001-5256.2021.11.004
[12]	Shuai CHEN, Changqing YANG. Drug-induced liver injury: Advances and confusions in treatment[J]. Journal of Clinical Hepatology, 2021, 37(11): 2505-2509. doi: 10.3969/j.issn.1001-5256.2021.11.001
[13]	Luyuan WANG, Minjie JIANG, Pujun GAO. Association between human leukocyte antigen gene polymorphism and drug-induced liver injury[J]. Journal of Clinical Hepatology, 2021, 37(2): 475-479. doi: 10.3969/j.issn.1001-5256.2021.02.048
[14]	Ying TENG, Xiaoyan DING, Wendong LI, Jinglong CHEN. Clinical effect of programmed cell death-1 inhibitor combined with lenvatinib in treatment of advanced primary liver cancer and related adverse events[J]. Journal of Clinical Hepatology, 2021, 37(3): 606-610. doi: 10.3969/j.issn.1001-5256.2021.03.020
[15]	Ji TongTong, Lu HaiYing, Tan Ning, Yu YanYan, Xu XiaoYuan. A comparative analysis of the clinical features of acute and chronic drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(7): 1556-1561. doi: 10.3969/j.issn.1001-5256.2020.07.021
[16]	Zhang Yu, Shao YueMing, Qin TingTing, Yin Xin, Wen XiaoYu. Current research status and application value of cytokines in drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(8): 1883-1886. doi: 10.3969/j.issn.1001-5256.2020.08.045
[17]	Wang QiaoLing, Zou ZhengSheng. Association between cytochrome P450 gene polymorphism and drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(5): 1150-1153. doi: 10.3969/j.issn.1001-5256.2020.05.045
[18]	Du XiaoFei, Chen Jie, Huang ChunYang, Zhang XiaoDan, Liu Dan, Bian XinQu, Han Ying, Liu YanMin, Dan Jing. Clinical effect and safety of magnesium isoglycyrrhizinate in treatment of autoimmune-like drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(6): 1330-1333. doi: 10.3969/j.issn.1001-5256.2020.06.028
[19]	Xing Lu, Wang Yu, Tao YanYan, Liu ChengHai. Clinical evaluation and prognosis prediction of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2019, 35(12): 2820-2823. doi: 10.3969/j.issn.1001-5256.2019.12.039
[20]	An LinJing, Zhang Xin, Yang Ying, Sha HuaYan, Huang Shun, Wang YaDong. Clinical significance of the management of adverse events and symptom cluster associated with advanced hepatocellular carcinoma after lenvatinib treatment[J]. Journal of Clinical Hepatology, 2019, 35(7): 1505-1508. doi: 10.3969/j.issn.1001-5256.2019.07.017

Supplements(0)

Cited By

Cited by
Periodical cited type(1)
1. 刘彬彬，高文，徐小元，刘建湘. 新型冠状病毒感染（COVID-19）流行期间妊娠期肝生化指标异常情况分析. 临床肝胆病杂志. 2024(01): 104-109 . 本站查看
Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(3) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (823) PDF downloads(84)

Identification and analysis of the risk of liver-related adverse drug reaction in pregnant women

DOI: 10.3969/j.issn.1001-5256.2022.08.021

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content